Prihlásiť sa Zaregistrujte sa zadarmo

Hotovosť na akciu spoločnosti SinoMab BioScience

Aká je hodnota metriky Hotovosť na akciu spoločnosti SinoMab BioScience?

Hodnota metriky Hotovosť na akciu spoločnosti SinoMab BioScience Limited je 0.44

Aká je definícia metriky Hotovosť na akciu?

Hotovosť na akciu (Cash per share) je pomer ihneď dostupných peňazí prístupných na výdaj a vydaných akcií spoločnosti.

Cash per share, sometimes called the cash share ratio, is the total cash per share. Cash on hand is reported on the balance sheet. Cash per share is calculated by dividing cash on hand by the total number of shares. Cash per share is the percentage of a firm's share price that is immediately accessible for spending. Cash per share consists of cash and short-term investments. It is money that a firm has on hand and does not come from borrowing or financing activities.

When a firm has a high cash per share, significant percentage of its assets is in a very liquid form. This can indicate economic uncertainty and unwillingness to invest given the current economic climate. High levels of cash per share can indicate that a firm is performing well and is able to reinvest in itself but high cash per share does not always indicate overall financial strength.

Hotovosť na akciu spoločností v sektore Health Care sektor na HKSE v porovnaní so spoločnosťou SinoMab BioScience

Čomu sa venuje spoločnosť SinoMab BioScience?

SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.

Firmy s metrikou hotovosť na akciu podobnou spoločnosti SinoMab BioScience



  • Hodnota metriky Hotovosť na akciu spoločnosti Amplitude Surgical SA je 0.44
  • Hodnota metriky Hotovosť na akciu spoločnosti First je 0.44
  • Hodnota metriky Hotovosť na akciu spoločnosti First je 0.44
  • Hodnota metriky Hotovosť na akciu spoločnosti CITIC Dameng je 0.44
  • Hodnota metriky Hotovosť na akciu spoločnosti Crown ElectroKinetics je 0.44
  • Hodnota metriky Hotovosť na akciu spoločnosti Man Wah je 0.44
  • Hodnota metriky Hotovosť na akciu spoločnosti SinoMab BioScience je 0.44
  • Hodnota metriky Hotovosť na akciu spoločnosti Dafeng Port Heshun Technology je 0.44
  • Hodnota metriky Hotovosť na akciu spoločnosti e CIOA je 0.44
  • Hodnota metriky Hotovosť na akciu spoločnosti NorthWestern je 0.44
  • Hodnota metriky Hotovosť na akciu spoločnosti Solid State Plc je 0.44
  • Hodnota metriky Hotovosť na akciu spoločnosti Glencore plc je 0.44
  • Hodnota metriky Hotovosť na akciu spoločnosti QSC AG je 0.44